FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression

This open-label observational trial (n=20) will investigate the effects of intravenous ketamine on treatment-resistant bipolar depression, with an interventional component of functional magnetic resonance imaging (fMRI).

The study, conducted by Brian Barnett at The Cleveland Clinic, aims to assess changes in brain connectivity following ketamine treatment.

Participants will receive ketamine infusions twice weekly for three weeks. Responders—those experiencing a ≥50% reduction in depression severity (QIDS-SR-16 score)—will undergo an additional three weeks of weekly ketamine infusions. fMRI scans will be performed before the first infusion and after the initial treatment phase to evaluate neurobiological changes. The study is expected to complete enrolment by December 2025.

Topic Depression Treatment-Resistant Depression Bipolar Disorder Neuroscience
Compound Ketamine
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

The Cleveland Clinic
This company doesn't have a full profile yet, it is linked to a clinical trial.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.